From a reactive to a proactive safety approach. Analysis of medication errors in chemotherapy using general failure types. | AHRQ Patient Safety Network

From a reactive to a proactive safety approach. Analysis of medication errors in chemotherapy using general failure types. | AHRQ Patient Safety Network

• Study
 
• Published August 2015

From a reactive to a proactive safety approach. Analysis of medication errors in chemotherapy using general failure types.

Fyhr A, Ternov S, Ek Å. Eur J Cancer Care (Engl). 2015 Aug 4; [Epub ahead of print].

This study applied a novel theoretical framework to medication errors involving chemotherapy drugs to characterize underlying causes. The authors found that working conditions often contributed to medication errors, consistent with prior studies of high-risk medications. These results suggest that vulnerabilities remain despite longstanding focus on safe administration of chemotherapy.

• PubMed citation
• Available at

Related Resources

JOURNAL ARTICLE › STUDY

Impact of automated dispensing cabinets on medication selection and preparation error rates in an emergency department: a prospective and direct observational before-and-after study.

Fanning L, Jones N, Manias E. J Eval Clin Pract. 2015 Sep 7; [Epub ahead of print].

NEWSPAPER/MAGAZINE ARTICLE

Medication errors affecting pediatric patients: unique challenges for this special population.

Grissinger M. PA-PSRS Patient Saf Advis. September 2015;12:96-102.

JOURNAL ARTICLE › REVIEW

Systematic review on the prevalence, frequency and comparative value of adverse events data in social media.

Golder S, Norman G, Loke YK. Br J Clin Pharmacol. 2015;80:878-888.

PRESS RELEASE/ANNOUNCEMENT

FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor).

MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; July 30, 2015.

JOURNAL ARTICLE › STUDY

Drug manufacturers' delayed disclosure of serious and unexpected adverse events to the US Food and Drug Administration.

Ma P, Marinovic I, Karaca-Mandic P. JAMA Intern Med. 2015;175:1565-1566.

View More